Abstract
BackgroundBranebrutinib (BMS-986195) is a highly potent and selective irreversible small-molecule covalent inhibitor of Bruton’s tyrosine kinase (BTK),1 a non-receptor tyrosine kinase involved in the pathophysiology of immune-mediated diseases. Branebrutinib has...
Published Version (Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have